Jaeken Jaak, Matthijs Gert
Department of Pediatrics, Center for Metabolic Disease, University of Leuven, Leuven, Belgium.
Annu Rev Genomics Hum Genet. 2007;8:261-78. doi: 10.1146/annurev.genom.8.080706.092327.
Congenital disorders of glycosylation (CDG) are a large family of genetic diseases resulting from defects in the synthesis of glycans and in the attachment of glycans to other compounds. These disorders cause a wide range of human diseases, with examples emanating from all medical subspecialties. Since our 2001 review on CDG ( 36 ), this field has seen substantial growth: The number of N-glycosylation defects has doubled (from 6 to 12), five new O-glycosylation defects have been added to the two previously known ones, three combined N- and O-glycosylation defects have been identified, the first lipid glycosylation defects have been discovered, and a new domain, that of the hyperglycosylation defects, has been introduced. A number of CDG are due to defects in enzymes with a putative glycosyltransferase function. There is also a growing group of patients with unidentified defects (CDG-x), some with typical clinical presentations and others with presentations not seen before in CDG. This review focuses on the clinical, biochemical, and genetic characteristics of CDG and on advances expected in their future study and clinical management.
先天性糖基化障碍(CDG)是一大类遗传性疾病,由聚糖合成缺陷以及聚糖与其他化合物连接缺陷所致。这些疾病引发了广泛的人类疾病,涵盖了所有医学亚专业领域。自我们2001年关于CDG的综述(36)发表以来,该领域取得了显著进展:N-糖基化缺陷的数量增加了一倍(从6种增至12种),在之前已知的两种O-糖基化缺陷基础上又新增了5种,已鉴定出3种N-糖基化和O-糖基化联合缺陷,首次发现了脂质糖基化缺陷,并且引入了一个新的领域,即高糖基化缺陷领域。许多CDG是由具有假定糖基转移酶功能的酶缺陷引起的。还有越来越多的患者存在未明确的缺陷(CDG-x),其中一些具有典型临床表现,另一些则具有CDG中未曾见过的表现。本综述重点关注CDG的临床、生化和遗传特征,以及预期在其未来研究和临床管理方面取得的进展。